Newsletters
The Capitalist Newsletter – March 21, 2017
TRUMP’S PICK FOR SUPREME COURT, NEIL GORSUCH, STARTS HEARING; HERE’S HOW IT WENT |
|
Winners & Losers – Esperion Therapeutics, Inc. (ESPR) Soars UP (74.14%) After Seeing Clear Path Through FDA for Heart Drug with Data From Trials Currently Underway – Aevi Genomic Medicine, Inc. (GNMX) Crashes DOWN (59.37%) After Company Announces Failed Clinical Trial for its Lead Drug Most Talked About Esperion Therapeutics, Inc. (ESPR) Considered a Majority Strong Buy After Data From Trials Currently Underway Shows Clear Path for FDA Approval The TIP Sheets – Monday, March 20th – Nektar Therapeutics (NKTR) Jumps UP (42.65%) After Upbeat Clinical Data for Drug to Help Treat Moderate to Severe Chronic Lower Back Pain. Expect Shares to Continue UP Unusual Volume Esperion Therapeutics, Inc. (TGTX) Soars UP (74.14%) on 30.5m Shares Traded After Extremely Positive Drug Trial Results Hint at Clear FDA Approval Path. The Drug is an LDL Cholesterol Lowering Treatment Which Would be Significantly More Cost Effective Than the Recent Amgen Heart Drug. Expect Shares to Continue UP |